Company profile
INOVIO PHARMACEUTICALS, INC.
NASDAQ:INOBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BIZALIMOGENE RALAPLASMID | phase3 | — | 7 | no active trials |
| RELUSCOVTOGENE RALAPLASMID | phase2_3 | — | 3 | completed, terminated, withdrawn |
| ROCAKINOGENE SIFUPLASMID | phase1_2 | — | 5 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (27)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01403155 | phase1 | completed | 2011-05-01 | 2012-08-01 | Inovio Pharmaceuticals | A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001 |
| NCT01405885 | phase1 | completed | 2011-05-01 | 2013-08-01 | Inovio Pharmaceuticals | A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus |
| NCT02172911 | phase1_2 | completed | 2014-06-06 | 2017-09-07 | Inovio Pharmaceuticals | A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer |
| NCT01304524 | phase2 | completed | 2011-04-01 | 2014-05-01 | Inovio Pharmaceuticals | A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 |
| NCT04093076 | phase1 | completed | 2021-01-27 | 2022-10-14 | Inovio Pharmaceuticals | Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana |
FDA applications (0)
No records yet.